ATP13A2 and Parkinson disease: Similarly, another non-inhibitory small molecule chaperone (named NCGC00188758) promoted GCase activity in lysosomes, reduced glucosylceramide levels, and increased the clearance of pathological α-Syn in cell lines derived from PD noncarriers and PD patients carrying mutations in SNCA (triplication or A53T), GBA, or PARK9 genes [223].